No Data
Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Express News | Alnylam Canada Signs Letter of Intent From Pan-Canadian Pharmaceutical Alliance for the Public Reimbursement of Amvuttra® for the Treatment of Hereditary Transthyretin-Mediated (Hattr) Amyloidosis in Adults
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
Press Release: Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study